Literature DB >> 24597854

Economic consequences incurred by living kidney donors: a Canadian multi-center prospective study.

S Klarenbach1, J S Gill, G Knoll, T Caulfield, N Boudville, G V R Prasad, M Karpinski, L Storsley, D Treleaven, J Arnold, M Cuerden, P Jacobs, A X Garg.   

Abstract

Some living kidney donors incur economic consequences as a result of donation; however, these costs are poorly quantified. We developed a framework to comprehensively assess economic consequences from the donor perspective including out-of-pocket cost, lost wages and home productivity loss. We prospectively enrolled 100 living kidney donors from seven Canadian centers between 2004 and 2008 and collected and valued economic consequences ($CAD 2008) at 3 months and 1 year after donation. Almost all (96%) donors experienced economic consequences, with 94% reporting travel costs and 47% reporting lost pay. The average and median costs of lost pay were $2144 (SD 4167) and $0 (25th-75th percentile 0, 2794), respectively. For other expenses (travel, accommodation, medication and medical), mean and median costs were $1780 (SD 2504) and $821 (25th-75th percentile 242, 2271), respectively. From the donor perspective, mean cost was $3268 (SD 4704); one-third of donors incurred cost >$3000, and 15% >$8000. The majority of donors (83%) reported inability to perform usual household activities for an average duration of 33 days; 8% reported out-of-pocket costs for assistance with these activities. The economic impact of living kidney donation for some individuals is large. We advocate for programs to reimburse living donors for their legitimate costs.
© 2014 The Authors. American Journal of Transplantation Published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons.

Entities:  

Keywords:  Cost of illness; costs and cost analysis; kidney transplantation; living donors

Mesh:

Year:  2014        PMID: 24597854      PMCID: PMC4285205          DOI: 10.1111/ajt.12662

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


Introduction

Transplantation is the preferred treatment for patients with kidney failure, given the reduced risk of death 1, improved quality of life and reduced healthcare costs 2 compared with dialysis. Each kidney transplanted into a patient with end-stage renal disease is estimated to provide an additional 2–3.5 quality-adjusted life years, direct healthcare savings of $100 000 3 and economic value of approximately $300 000 4. Despite strategies to increase organs available for transplantation for both living and deceased donation 5–7, the need for kidneys continues to exceed their supply 8. Potential living donors and their intended recipients are concerned about economic consequences of donation 9. It has been recognized that living donors experience economic consequences during workup, surgery and convalescence. These economic consequences may be considered unfair and act as a disincentive for some donors. It has been suggested that living donors be reimbursed for their incurred expenses in jurisdictions where this is feasible 10,11. We published a comprehensive, critical review of the existing 35 studies describing the frequency and magnitude of expenses incurred by living donors 12; however, an accurate estimate of costs was not possible given the multiple methodological issues in existing studies, including the retrospective nature of most reports, lengthy time frames for patient recall, low response rates and incomplete capture of all relevant costs. As such the true extent and magnitude of the economic burden to living kidney donors are uncertain, highlighting the need for prospective and accurate determination of these costs 13. Given the poor health outcomes for patients on dialysis, limited supply of deceased donor organs and high costs of dialysis therapy, it is imperative that all barriers to living organ donation be identified, fully characterized and definitively addressed. Better knowledge of the economic consequences experienced by living kidney donors also informs the feasibility and conduct of emerging and existing reimbursement programs. As part of a larger prospective multi-center study designed to determine the medical and psychosocial consequences of living kidney donation, we conducted a rigorous prospective costing study to obtain precise estimates of the expenses incurred by Canadian living kidney donors.

Methods

Economic consequences incurred were determined from participants enrolled in a multi-center prospective study designed to determine long-term outcomes in living donors. Briefly, subjects ≥18 years of age deemed eligible to donate a kidney to a relative or friend at one of seven Canadian transplant centers, who verbally communicated in English or French, and provided consent, were recruited prior to donation and followed post–kidney donation. This economic sub-study examined the first 100 living kidney donors enrolled who proceeded with donation and had follow-up for at least 1 year. The three-step micro-costing approach of identification, measurement and valuation of resources 14 was followed. Identification of potential economic consequences was determined through systematic review of existing literature 12 and iterative consultation with healthcare professionals in transplantation to identify categories and details of potential costs (Figure S1; Table S1). Measurement of resources consumed by donors was performed through two mail self-administered surveys at 3 and 12 months after kidney donation, based on the observation that the majority of costs due to donation are encountered within the first 3 months of donation, and almost all within the first 12 months. A 90-day period for self-reported productivity impairment has an intraclass correlation coefficient of over 0.80 with actual records 15, indicating that participants are likely to accurately recall expenses occurring in the 3 months postdonation. Donors reported for the predonation (including donor evaluation), donation and postdonation time periods. Follow-up telephone calls to participants were made by the central data-coordinating center for missing or discrepant data. We identified the major cost categories relevant to living donors, including direct costs defined as resources consumed in the donation process even where a direct monetary transaction does not occur, and productivity costs including days off work with (and without) lost income, lost home productivity, as well as caregiver for convalescent or dependent care (Table S1). Workforce productivity was valued using province-specific average wage rates (Table S2). We developed a comprehensive instrument using accepted techniques to capture units of resources consumed as a result of living donation 14–16. This instrument quantified the number of units consumed in each category by donors for a full accounting of resource utilization. Collecting units consumed (e.g. capturing distance traveled instead of out-of-pocket fuel costs) facilitates portability of the results to alternate settings, as the monetary value per unit may vary depending on setting and region. Finally, we assigned each resource unit a cost using conventional costing techniques and relevant Canadian estimates (Table S1 and Supplemental Methods). The cost incurred for living kidney donors was calculated by each cost category and in total using the average and standard deviation as well as median and range (given that cost data are frequently skewed). We determined the frequency distribution of total costs incurred by each donor. The value of lost workforce productivity where the donor did not incur lost wages was determined but was not included in total cost in the primary analysis.

Results

Among donors with at least 1 year of follow-up postdonation, 85% had complete 1-year data at the time of this analysis. The 100 living kidney donors enrolled had an average age of 45.2 years, and 64% were Caucasian women (Table1). They were enrolled from 2004 to 2008, and all costs are expressed in Canadian dollars for this period of time. The most frequently reported household annual income category was ≥$80 000; at this time, the average household income in Canada was $71 600–$78 500 17. The majority of donors were from four transplantation centers in Ontario. Direct out-of-pocket costs were incurred by 94 of the 100 subjects, with highest proportion reporting cost for ground travel (94%) and nonhospital accommodation (49%) (Table2). For donors who reported resource use in cost category of interest, the greatest average costs were observed for ground travel, accommodation and air travel ($897, $1759 and $1480, respectively). When considering all donors (including those who incurred no resource use), the largest costs were for ground travel and accommodation ($852 and $862, respectively). In all 100 donors, average direct cost was $1780 (SD 2504), and median cost was $821 (25th–75th percentile 242–2271).
Table 1

Characteristics of living kidney donors

VariableN = 100 donors
Age at time of donation, mean (SD)45.2 (9.5)
Female, n71
Race/ethnicity, n
 Caucasian90
 Asian3
 African Canadian/American, Black2
 Other4
Married prior to donation, n74
Family income prior to donation (CAD), n
 <15 0002
 15 000–29 9996
 30 000–49 99922
 50 000–79 99921
 ≥80 00048
Relationship to recipient
 Sibling38
 Parent16
 Son/daughter14
 Spouse/partner12
 Friend4
 Other15
Transplant center, n
 Edmonton11
 Halifax8
 Hamilton11
 London34
 Toronto (St. Michael’s)12
 Vancouver11
 Winnipeg13
Province of residence, n
 Alberta11
 British Columbia11
 Manitoba12
 Nova Scotia4
 Ontario59
 Prince Edward Island1
 Out of country (USA)1

One donor is missing age, gender, race and annual household income.

All respondents were English speaking.

Direct economic costs for 100 Canadian living kidney donors

Cost typeCost categoryDescriptionNumber of patients (n = 100)UnitsMedian (25th–75th percentile) unitsCosts $ (in patients reporting outcome)Costs $ (all patients)
Average (SD)Median (25th–75th percentile)Average (SD)Median (25th–75th percentile)Average (SD)Median (25th–75th percentile)
Direct1780 (2504)821 (242–2271)
TravelGround travel94# Return trips10 (6–16)897 (1048)512 (216–1187)852 (1040)486 (194–1080)
Air travel3# Return trips3 (1–4)1480 (1108)2065 (203–2173)44 (299)0 (0–0)
AccommodationNonhospital accommodation49# Overnight stays6 (3–11)1759 (2567)1094 (547–2007)862 (1995)0 (0–1090)
MedicationPain medication or antibiotics4Drugs taken (yes/no)N/A40 (28)40 (20–60)1 (6)0 (0–0)
MedicalOut-of-pocket medical expenses related to tests, appointments or hospital stays22Expenses incurred (yes/no)N/A152 (247)60 (40–150)30 (123)0 (0–0)

Table 1Considers only those donors who reported the resource use.

Table 2Considers all donors (n = 100) in denominator (one donor experienced exceptional circumstances [out of country donor with 3-month stay] and these costs were excluded).

Table 3Medication includes only patients who paid for medication out of pocket, and some or all of the cost of medication was not reimbursed. Note that 30 out of 100 donors reported requiring medication. Two out of four donors are missing cost of medication.

Work and home productivity losses occurred in over 80% of subjects (Table3), and lost wages was reported by 47% of donors. In those who experienced loss of pay, the average number of days and income lost were 20 and $4567, respectively; for all donors average lost wage was $2144. Total workforce productivity loss that includes time off work with and without pay (i.e. vacation, sick leave, employment insurance) for all donors was $6729 (Table4).

Economic outcomes for 100 Canadian living kidney donors

Cost typeCost categoryDescriptionNumber of donors reporting the outcomeNumber of days (in donors reporting outcome)Number of days (all donors)Costs $ (in donors reporting outcome)Costs $ (all donors)
Median (25th–75th percentile)Median (25th–75th percentile)Average (SD)Median (25th–75th percentile)Average (SD)Median (25th–75th percentile) CostAverage (SD)Median (25th–75th percentile)
IndirectLost wages6729 (6259)6572 (1048–9081)
Time spent away from work (with loss of pay)472004567327321440
(5–44)(0–14)(5111)(850–7484)(4167)(0–2794)
Time spent away from work (without loss of pay)6838156898665945582517
(14–53)(0–46)(5448)(2288–8522)(5753)(0–7816)
Housework and dependent care5233 (5196)3345 (838–8557)
Days unable to perform usual household activities (estimated cost)8333236597576354533977
(14–60)(6–56)(5053)(2445–9780)(5231)(1116–9014)
Number of days requiring assistance or care (reported out-of-pocket cost)87037253230
(6–12)(0–0)(800)(0–125)(202)(0–0)

Table 1Considers only those donors who reported the resource use.

Table 2Considers all donors (n = 100) in denominator.

Total costs incurred for living kidney donors

ScenarioAverage cost $ (SD)Median cost $ (25th–75th percentile)
Donor costs3268 (4704)1282 (205–4619)
Estimated home productivity cost5521 (5287)4462 (1222–9014)
Total workforce productivity cost6729 (6259)6572 (1048–9081)

Considers all donors (n = 100) in denominator.

Table 1Donor costs = out-of-pocket costs + lost wages.

Table 2Home productivity determined using provincial wage rates.

Table 3Includes time off work with and without pay.

Approximately 45% of donors directly experienced economic consequences attributable to living kidney donation (out-of-pocket costs, lost pay, but excluding home productivity costs) that were less than $1000 (Figure 1). However, 20% incurred costs between $1000 and $3000, 34% experienced costs >$3000, with 15% of those incurring costs >$8000. The average out-of-pocket costs and lost wages for living donors was $3268 (median $1282) (Table 4). In sensitivity analysis, mean home productivity cost was estimated at $5521.
Figure 1

Frequency distribution of total costs incurred from the living kidney donor perspective. 25th percentile: $205; median: $1282; 75th percentile: $4619. Average (SD): $3268 (4704). Five donors incurred 0 costs. Excludes home productivity costs and time off work where no pay was lost. One donor experienced exceptional circumstances (out-of-country donor with 3-month stay) and these costs were excluded.

Characteristics of living kidney donors One donor is missing age, gender, race and annual household income. All respondents were English speaking. Direct economic costs for 100 Canadian living kidney donors Table 1Considers only those donors who reported the resource use. Table 2Considers all donors (n = 100) in denominator (one donor experienced exceptional circumstances [out of country donor with 3-month stay] and these costs were excluded). Table 3Medication includes only patients who paid for medication out of pocket, and some or all of the cost of medication was not reimbursed. Note that 30 out of 100 donors reported requiring medication. Two out of four donors are missing cost of medication.

Interpretation

To our knowledge, this is the first study to prospectively and comprehensively capture and value the economic consequences experienced by living kidney donors. While there is considerable variation between donors in what costs are encountered and their magnitude, the vast majority of living kidney donors directly experienced substantial economic consequences, with an estimated average value of costs of $3268 for all 100 Canadian living donors in this study. We also identified a wide variation in costs incurred in both overall costs as well as costs in the categories examined. While a large proportion incurred costs valued at <$1000, one-third of donors experienced a large economic burden in excess of $5000 or $10 000 as a result of donation. Economic outcomes for 100 Canadian living kidney donors Table 1Considers only those donors who reported the resource use. Table 2Considers all donors (n = 100) in denominator. Total costs incurred for living kidney donors Considers all donors (n = 100) in denominator. Table 1Donor costs = out-of-pocket costs + lost wages. Table 2Home productivity determined using provincial wage rates. Table 3Includes time off work with and without pay. We 10, as well as others 18, have advocated for reimbursement of incurred expenses on both the principle of fairness, as well as eliminating a potential barrier or disincentive to living kidney donation. The economic consequences enumerated here are not trivial, and the context in which they occur is worth noting. Biological relatives and spouses make up the majority of living donors, who may be burdened financially by the burden of the chronic illness of end-stage renal disease. Further, living kidney donation leads not only to better quality and quantity of life for recipients but also to substantial net healthcare cost savings estimated at $100 000 3. It is counterintuitive to allow economic penalties to occur to living kidney donors when programs are attempting to heavily promote this activity that results in health improvements and healthcare resource savings. Frequency distribution of total costs incurred from the living kidney donor perspective. 25th percentile: $205; median: $1282; 75th percentile: $4619. Average (SD): $3268 (4704). Five donors incurred 0 costs. Excludes home productivity costs and time off work where no pay was lost. One donor experienced exceptional circumstances (out-of-country donor with 3-month stay) and these costs were excluded. Several living donor reimbursement programs have emerged in Canada since our study began, and while this is an important step forward, the conduct of new and existing programs can be informed by this study. We are aware that many of these programs have caps in place for reimbursement by cost category and overall in an attempt to maintain sustainability, with caps often of ∼$5500 per donor. While our data indicate that this is sufficient for the majority of donors, there are a proportion of donors who experience costs that exceed these caps. While sustainability is a critical consideration, it is not equitable that donors who incur higher costs should be penalized. Examples of these scenarios encountered in this cohort include individuals unable to obtain time off work with pay, or an out-of-country donor who was required to stay near the transplant center for almost 3 months postdonation and incurred high costs due to this. We would argue that all reasonable costs as a result of living kidney donation be reimbursed, without penalizing those in whom circumstances lead to a greater magnitude of these costs. There are limitations of this study. First, there may be recall bias for participants. We attempted to minimize this by utilizing a short recall time frame of 3 months 15 during the time when most losses would occur, and requesting identification of units of resources to minimize the cognitive burden of calculating costs. This also allows portability of results to different jurisdictions where the cost per unit (hotel night, airline travel) may differ. Second, these data are reflective of participants enrolled in a larger observational study, and it is not clear that results would be generalizable to all donors. For example, it is surprising that donors traveling by air would have a median of three round trips, although air travel was reported by only three donors. Further, Canada is geographically large and many donors may travel longer than in more densely populated areas. However, study inclusion criteria are broad, and donor characteristics are similar to typical living kidney donors in Canada. Third, economic consequences may be greater for living donor paired exchange, where travel distances may be greater and the donor frequently brings a support person; this practice was nonexistent in Canada during the study enrollment period. Finally, medical costs were not considered as Canada has a single payer universal healthcare system. Incurred costs may be higher in other jurisdictions, which may be a critically important consideration 19 given the recommendations of lifelong medical surveillance of living kidney donors for adverse medical consequences, such as hypertension. Currently in Canada recommended practice is follow-up at 4–12 weeks and 1 year, followed by annual follow-up with a medical practitioner 20; other jurisdictions such as the Organ Procurement and Transplantation Network mandate follow-up for 2 years. While we do not have data from our study on these costs beyond 1 year (or other cost related to disability or death that rarely occur with living donation), we support provision of short-term and long-term medical insurance for living kidney donors. While uncertainty exists regarding the optimal method of valuing and reimbursing lost home or workforce productivity, we adhered to accepted practice. First, we used average provincial wage rates to determine cost, not actual wage rates. For reimbursement purposes, it is not clear if actual wages should be reimbursed, or if a standard wage rate or set stipend should be provided. Potential benefits of a stipend are that it would compensate home productivity losses without requiring measurement, may mitigate unfairly undercompensating nonemployed donors (which in our sample were primarily female—the predominant gender of donors), and may particularly serve those with little or no home productivity support. Due to poor response we do not have actual wages, and argue that the main purpose of reimbursing lost wages is to prevent financial hardship in a sustainable fashion. As some donors may have a very high income, reimbursing actual income may not be feasible or desirable. From an economic perspective nonpaid labor (such as home productivity) has real value, which a set stipend may address, if allowable by interpretation of existing legislation. Second, we examined the value of time off work that did not result in a loss of wages to the donor in scenario analysis. We are aware of many donors who use sick leave, vacation time or employment insurance to avoid lost wages. Arguably donors should not have to utilize these privileges, which have quantifiable economic value, for the act of donation, but retain them for their intended use or to utilize when required at a future date (e.g. retain the ability to take future sick leave due to unrelated reasons). Finally, we did not include the value of home productivity, as the true economic value of this activity is not clear. If lost home productivity is valued in the same manner as workforce productivity, the mean and median values are $5233 and $3345, respectively. However, if these activities are assumed by other household members, this may be an overestimate. Further, from a strictly economic perspective, this has a nonzero value; it is not commonly used or advocated for in donor reimbursement programs, despite the fact that is of real value. In conclusion, we present the first high-quality comprehensive prospective assessment of the economic consequences in 100 Canadian living kidney donors from seven centers. Economic consequences are frequent and nontrivial, with a sizable proportion of donors experiencing significant costs. These results further support the development of donor reimbursement programs and can be used to guide their implementation.
  16 in total

Review 1.  Expanded criteria donors for kidney transplantation.

Authors:  Robert A Metzger; Francis L Delmonico; Sandy Feng; Friedrich K Port; James J Wynn; Robert M Merion
Journal:  Am J Transplant       Date:  2003       Impact factor: 8.086

2.  Living organ donors face financial barriers: a national reimbursement policy is needed.

Authors:  Scott Klarenbach; Amit X Garg; Sorina Vlaicu
Journal:  CMAJ       Date:  2006-03-14       Impact factor: 8.262

Review 3.  The measurement of indirect costs in the health economics evaluation literature. A review.

Authors:  P Jacobs; K Fassbender
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

4.  A study of the quality of life and cost-utility of renal transplantation.

Authors:  A Laupacis; P Keown; N Pus; H Krueger; B Ferguson; C Wong; N Muirhead
Journal:  Kidney Int       Date:  1996-07       Impact factor: 10.612

5.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

Authors:  R A Wolfe; V B Ashby; E L Milford; A O Ojo; R E Ettenger; L Y Agodoa; P J Held; F K Port
Journal:  N Engl J Med       Date:  1999-12-02       Impact factor: 91.245

6.  The accuracy of self-reported disability days.

Authors:  D A Revicki; D Irwin; J Reblando; G E Simon
Journal:  Med Care       Date:  1994-04       Impact factor: 2.983

7.  Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury.

Authors:  Walter D Park; Joseph P Grande; Dora Ninova; Karl A Nath; Jeffrey L Platt; James M Gloor; Mark D Stegall
Journal:  Am J Transplant       Date:  2003-08       Impact factor: 8.086

8.  The general public's concerns about clinical risk in live kidney donation.

Authors:  L Ebony Boulware; Lloyd E Ratner; Julie Ann Sosa; Alexander H Tu; Satish Nagula; Christopher E Simpkins; Raegan W Durant; Neil R Powe
Journal:  Am J Transplant       Date:  2002-02       Impact factor: 8.086

9.  Cost-effectiveness of organ donation: evaluating investment into donor action and other donor initiatives.

Authors:  James F Whiting; Bryce Kiberd; Zoltan Kalo; Paul Keown; Leo Roels; Maria Kjerulf
Journal:  Am J Transplant       Date:  2004-04       Impact factor: 8.086

Review 10.  Financial considerations in living organ donation.

Authors:  Cheryl Jacobs; Charlie Thomas
Journal:  Prog Transplant       Date:  2003-06       Impact factor: 1.065

View more
  23 in total

1.  Living-Donor Kidney Transplantation: Reducing Financial Barriers to Live Kidney Donation--Recommendations from a Consensus Conference.

Authors:  Lara Tushla; Dianne LaPointe Rudow; Jennifer Milton; James R Rodrigue; Jesse D Schold; Rebecca Hays
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-22       Impact factor: 8.237

2.  Financial Costs Incurred by Living Kidney Donors: A Prospective Cohort Study.

Authors:  Sebastian Przech; Amit X Garg; Jennifer B Arnold; Lianne Barnieh; Meaghan S Cuerden; Christine Dipchand; Liane Feldman; John S Gill; Martin Karpinski; Greg Knoll; Charmaine Lok; Matthew Miller; Mauricio Monroy; Chris Nguan; G V Ramesh Prasad; Sisira Sarma; Jessica M Sontrop; Leroy Storsley; Scott Klarenbach
Journal:  J Am Soc Nephrol       Date:  2018-11-07       Impact factor: 10.121

3.  The Terrible Toll of the Kidney Shortage.

Authors:  Frank McCormick; Philip J Held; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2018-11-12       Impact factor: 10.121

4.  Mood, body image, fear of kidney failure, life satisfaction, and decisional stability following living kidney donation: Findings from the KDOC study.

Authors:  J R Rodrigue; J D Schold; P Morrissey; J Whiting; J Vella; L K Kayler; D Katz; J Jones; B Kaplan; A Fleishman; M Pavlakis; D A Mandelbrot
Journal:  Am J Transplant       Date:  2018-01-09       Impact factor: 8.086

5.  Emotional and Financial Experiences of Kidney Donors over the Past 50 Years: The RELIVE Study.

Authors:  Cheryl L Jacobs; Cynthia R Gross; Emily E Messersmith; Barry A Hong; Brenda W Gillespie; Peg Hill-Callahan; Sandra J Taler; Sheila G Jowsey; Tim J Beebe; Arthur J Matas; Jonah Odim; Hassan N Ibrahim
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-13       Impact factor: 8.237

Review 6.  Risks of Living Kidney Donation: Current State of Knowledge on Outcomes Important to Donors.

Authors:  Krista L Lentine; Ngan N Lam; Dorry L Segev
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-11       Impact factor: 8.237

7.  Predonation Direct and Indirect Costs Incurred by Adults Who Donated a Kidney: Findings From the KDOC Study.

Authors:  J R Rodrigue; J D Schold; P Morrissey; J Whiting; J Vella; L K Kayler; D Katz; J Jones; B Kaplan; A Fleishman; M Pavlakis; D A Mandelbrot
Journal:  Am J Transplant       Date:  2015-05-05       Impact factor: 8.086

Review 8.  Long-term medical risks to the living kidney donor.

Authors:  Ngan N Lam; Krista L Lentine; Andrew S Levey; Bertram L Kasiske; Amit X Garg
Journal:  Nat Rev Nephrol       Date:  2015-05-05       Impact factor: 28.314

9.  Social and Financial Outcomes of Living Liver Donation: A Prospective Investigation Within the Adult-to-Adult Living Donor Liver Transplantation Cohort Study 2 (A2ALL-2).

Authors:  A DiMartini; M A Dew; Q Liu; M A Simpson; D P Ladner; A R Smith; J Zee; S Abbey; B W Gillespie; R Weinrieb; M S Mandell; R A Fisher; J C Emond; C E Freise; A H Sherker; Z Butt
Journal:  Am J Transplant       Date:  2016-11-10       Impact factor: 8.086

10.  Decision aids to increase living donor kidney transplantation.

Authors:  Jennifer C Gander; Elisa J Gordon; Rachel E Patzer
Journal:  Curr Transplant Rep       Date:  2017-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.